EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer

Lei Zhao, Yifang Wang, Xin Sun, Xiujuan Zhang, Nicole Simone iD, Jun He iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25042382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Lei Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Genomic Medicine, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, ets-Domain Protein Elk-1, Gefitinib. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIEHS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of acquired resistance to small molecule tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) signaling has hindered their efficacy in treating non-small cell lung cancer (NSCLC) patients. Our previous study showed that constitutive activation of the 70 kDa ribosomal protein S6 kinase 1 (S6K1) contributes to the acquired resistance to EGFR-TKIs in NSCLC cell lines and xenograft tumors in nude mice. However, the regulatory mechanisms underlying S6K1 constitutive activation in TKI-resistant cancer cells have not yet been explored. In this study, we recapitulated this finding by taking advantage of a gefitinib-resistant patient-derived xenograft (PDX) model established through a number of passages in mice treated with increasing doses of gefitinib. The dissociated primary cells from the resistant PDX tumors (PDX-R) displayed higher levels of phosphor-S6K1 expression and were resistant to gefitinib compared to cells from passage-matched parental PDX tumors (PDX-P). Both genetic and pharmacological inhibition of S6K1 increased sensitivity to gefitinib in PDX-R cells. In addition, both total and phosphorylated mechanistic target of rapamycin kinase (MTOR) levels were upregulated in PDX-R and gefitinib-resistant PC9G cells. Knockdown of MTOR by siRNA decreased the expression levels of total and phosphor-S6K1 and increased sensitivity to gefitinib in PDX-R and PC9G cells. Moreover, a transcription factor ELK1, which has multiple predicted binding sites on the MTOR promoter, was also upregulated in PDX-R and PC9G cells, while the knockdown of ELK1 led to decreased expression of MTOR and S6K1. The chromatin immunoprecipitation (ChIP)-PCR assay showed the direct binding between ELK1 and the MTOR promoter, and the luciferase reporter assay further indicated that ELK1 could upregulate MTOR expression through tuning up its transcription. Silencing ELK1 via siRNA transfection improved the efficacy of gefitinib in PDX-R and PC9G cells. These results support the notion that activation of ELK1/MTOR/S6K1 signaling contributes to acquired resistance to gefitinib in NSCLC. The findings in this study shed new light on the mechanism for acquired EGFR-TKI resistance and provide potential novel strategies by targeting the ELK1/MTOR/S6K1 pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Non-Small-Cell Lungets-Domain Protein Elk-1GefitinibLung NeoplasmsTyrosine Kinase InhibitorsAnimalsHumansMiceCell Line, TumorCell ProliferationDrug Resistance, NeoplasmErbB ReceptorsMice, NudeRibosomal Protein S6 KinasesRNA, Small InterferingSirolimusTOR Serine-Threonine Kinases

Stichwörter der Autor:innen

EGFR-TKIELK1MTORS6K1gefitinibresistance

Substanzen

Antineoplastic AgentsELK1 protein, humanErbB Receptorsets-Domain Protein Elk-1GefitinibMTOR protein, humanRibosomal Protein S6 KinasesRNA, Small InterferingSirolimusTOR Serine-Threonine Kinases

Autor:innen und Institutionen

  • Department of Pathology and Genomic Medicine, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
  • Department of Medicine, Center for Translational Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA.
  • Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.

ORCID-Profile: Nicole Simone, Jun He

Förderung

  • NCI NIH HHS
  • NIEHS NIH HHS
  • NIH HHS
  • National Institutes of Health (NIH)

Zitieren

APA

Zhao, L., Wang, Y., Sun, X., Zhang, X., Simone, N., & He, J. (2024). ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25042382

Vancouver

Zhao L, Wang Y, Sun X, Zhang X, Simone N, He J. ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25042382

BibTeX
@article{Zhao2024,
  author = {Zhao, Lei and Wang, Yifang and Sun, Xin and Zhang, Xiujuan and Simone, Nicole and He, Jun},
  title = {ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25042382}
}
Kostenlos starten →